HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Omeprazole (Esomeprazole)

A highly effective inhibitor of gastric acid secretion used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-EXCHANGING ATPASE) in the proton pump of GASTRIC PARIETAL CELLS.

Also Known As:

Esomeprazole; Nexium; Prilosec; H 168-68; H 168 68; H 16868; 1H-Benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-

Networked: 2544 relevant articles (468 outcomes, 553 trials/studies) for this Drug, Comments

Relationship Network

Drug Context: Research Results

Experts

1.	Stolte, M: 14 articles (07/2006 - 01/2000)
2.	Armstrong, D: 13 articles (06/2009 - 02/2000)
3.	Lind, T: 11 articles (10/2008 - 07/2000)
4.	Lauritsen, K: 11 articles (09/2007 - 12/2000)
5.	Talley, N J: 10 articles (09/2007 - 10/2000)
6.	Sung, Joseph J Y: 9 articles (03/2010 - 12/2002)
7.	Labenz, J: 9 articles (06/2009 - 12/2000)
8.	Junghard, O: 9 articles (10/2008 - 12/2000)
9.	Kuipers, E J: 9 articles (04/2008 - 01/2000)
10.	Chan, Francis K L: 8 articles (01/2010 - 01/2002)

Related Diseases

1.	Duodenal Ulcer (Curling's Ulcer) 11/01/1992 - "It is concluded that omeprazole, even in the presence of adverse prognostic influences, results in significantly better healing of duodenal ulcer and relief from symptoms than H2-RA." 01/01/1994 - "As omeprazole is more effective than the H2-receptor antagonists in the acute treatment of duodenal ulcer, healing virtually all patients within 4 weeks (4), it may also be more effective in the maintenance treatment of duodenal ulcer disease. " 01/01/1989 - "Open studies using maintenance treatment with low-dose omeprazole suggest that such therapy is effective in keeping refractory duodenal ulcer healed." 03/01/1996 - "BACKGROUND & AIMS: Omeprazole is less effective in healthy subjects than in patients with duodenal ulcers. " 07/01/1991 - "Omeprazole is effective and safe in the treatment of gastric and duodenal ulcers." Order ALL the reference details at left...
2.	Gastroesophageal Reflux (GERD) 12/01/1995 - "In addition, studies also indicate that omeprazole is the most effective agent for the treatment of patients with GERD refractory to other treatments. " 01/01/1989 - "Several studies have clearly demonstrated that omeprazole is highly efficacious in the management of patients with gastro-oesophageal reflux disease. " 05/01/2008 - "GERD symptom scores were significantly improved from baseline to the final week of the study in all of the treatment groups (P < 0.01) CONCLUSIONS: In children ages 1 to 11 years with endoscopically proven GERD, esomeprazole (at daily doses of 5, 10, or 20 mg) was generally well tolerated. " 05/01/2008 - "OBJECTIVES: To evaluate safety, tolerability, and symptom improvement with once-daily esomeprazole in children with endoscopically proven gastroesophageal reflux disease (GERD). " 04/01/2000 - "AIM: To compare the omeprazole test to ambulatory 24-h oesophageal pH monitoring in diagnosing GERD in symptomatic patients using endoscopically proven erosive oesophagitis as a gold standard. " Order ALL the reference details at left...
3.	Ulcer 01/01/1989 - "In conclusion, omeprazole 20 mg each morning was found to be safe and highly effective for treatment of gastric and prepyloric ulcer in Korean patients, producing a 98% healing rate. " 01/01/1989 - "The healing efficacy of omeprazole was assessed in 57 Korean patients with endoscopically-proven gastric (GU) and/or prepyloric (PPU) ulcers of at least 5 mm diameter. " 04/01/1999 - "Horses treated with omeprazole had significantly (P < 0.01) more improvement in ulcer scores at the end of the study compared with controls. " 06/01/2005 - "DG showed significant protection against CRU (68.37%), AL (88.87%), ASP (38.2%), PL (40.63%) and HST (63.15%) induced ulcer models, whereas standard drug omeprazole (OMZ) showed protection index of 83.86, 56.35, 70.31 and 84.21%, respectively in CRU, ASP, PL and HST models. " 01/01/1998 - "CONCLUSIONS: Treatment with TAP plus omeprazole significantly decreases ulcer recurrence through TAP's improved mucosal restoration." Order ALL the reference details at left...
4.	Peptic Ulcer (Peptic Ulcers) 08/01/1999 - "CONCLUSION: Omeprazole triple therapy is highly effective in patients with active or healed peptic ulcer disease, and is well tolerated." 06/01/1990 - "It is concluded that omeprazole is highly effective in healing refractory peptic ulcers." 02/01/1987 - "It is therefore concluded that omeprazole is highly effective in healing refractory peptic ulcers and that omeprazole maintenance therapy may be useful for prevention of relapse. " 05/01/1998 - "CONCLUSION: Both standard and high doses of omeprazole are equally safe and effective regimens for the treatment of NSAID-induced gastroduodenal ulcers when anti-inflammatory treatment is not discontinued." 08/01/1988 - "From these results, omeprazole can be expected to be useful for the treatment of peptic ulcer disease." Order ALL the reference details at left...
5.	Hemorrhage 01/01/2008 - "Although data indicate that H2-receptor antagonists and omeprazole are effective in preventing clinically significant bleeding, evidence for an advantage with respect to length of hospital or intensive-care-unit stay, as well as mortality, is still lacking. " 01/18/1992 - "However, there was an unexpected but significant reduction in endoscopic signs of upper gastrointestinal bleeding in patients treated with omeprazole compared with those treated with placebo (236 (45%) placebo v 176 (33%) omeprazole; p less than 0.0001). " 01/01/2002 - "In a few studies, when given enterally/parenterally Omeprazole lowered rates of recurrent bleeding, surgery and the number and rate of blood units transfused. " 04/01/1997 - "RESULTS: When evaluated on day 3, the primary variable 'overall outcome' (based on an ordinal ranking scale; see Study variables) (P = 0.017) and the secondary variables, surgery (P = 0.003), degree (P = 0.004) and duration of bleeding (P = 0.003) all favored the omeprazole group. " 01/18/1992 - "Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Ranitidine (Zantac)
2.	Amoxicillin (Wymox)
3.	lansoprazole (Prevacid)
4.	Clarithromycin (Biaxin)
5.	pantoprazole (Protonix)
6.	Omeprazole (Esomeprazole)
7.	Metronidazole (Metric)
8.	Proton Pumps (Proton Pump)
9.	rabeprazole (Aciphex)
10.	Cimetidine (Biomet)

Related Therapies and Procedures

1.	Gastrectomy
2.	Oral Administration
3.	Fundoplication
4.	Aftercare (After-Treatment)
5.	Intravenous Infusions

blog comments powered by Disqus

TREATMENT OPTIONS
for Duodenal Ulcer,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 535 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>